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REVIEW CURRENTOPINION Pharmacologic epigenetic modulators of alkaline
phosphatase in chronic kidney diseasewww.co-nephrolhypertens.coma,b,c d d bMathias Haarhaus , Dean Gilham , Ewelina Kulikowski , Per Magnusson ,
and Kamyar Kalantar-Zadehe,f,gPurpose of review
In chronic kidney disease (CKD), disturbance of several metabolic regulatory mechanisms cause
premature ageing, accelerated cardiovascular disease (CVD), and mortality. Single-target interventions
have repeatedly failed to improve the prognosis for CKD patients. Epigenetic interventions have the
potential to modulate several pathogenetic processes simultaneously. Alkaline phosphatase (ALP) is a
robust predictor of CVD and all-cause mortality and implicated in pathogenic processes associated with
CVD in CKD.
Recent findings
In experimental studies, epigenetic modulation of ALP by microRNAs or bromodomain and extraterminal
(BET) protein inhibition has shown promising results for the treatment of CVD and other chronic metabolic
diseases. The BET inhibitor apabetalone is currently being evaluated for cardiovascular risk reduction in a
phase III clinical study in high-risk CVD patients, including patients with CKD (ClinicalTrials.gov Identifier:
NCT02586155). Phase II studies demonstrate an ALP-lowering potential of apabetalone, which was
associated with improved cardiovascular and renal outcomes.
Summary
ALP is a predictor of CVD and mortality in CKD. Epigenetic modulation of ALP has the potential to affect
several pathogenetic processes in CKD and thereby improve cardiovascular outcome.
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Chronic kidney disease (CKD) is a state of imbal-
ance of several important physiologic regulatory
mechanisms, among them mineral balance, acid–
base balance, nutritional balance, and energy bal-
ance, resulting in accelerated cardiovascular dis-
ease (CVD) and mortality. In addition, CKD is also
associated with chronic inflammation and resem-
bles a model for premature ageing [1,2]. In CKD,
numerous pathways are upregulated that are asso-
ciated with immunity and inflammation, oxida-
tive stress, endothelial dysfunction, vascular
calcification, and coagulation [3]. Pharmacologic
epigenetic modulation has the advantage of tar-
geting several disease-related processes simulta-
neously. Due to its expression in multiple tissues
and organs, which is upregulated in response to
different pathogenic stimuli, alkaline phosphatase
(ALP, EC 3.1.3.1) may be a suitable target for
epigenetic modulation (Fig. 1).Volume 29  Number 1  January 2020
KEY POINTS
 Circulating ALP is a robust risk marker for CVD and all-
cause mortality in the general population and in CKD.
 ALP is ubiquitously expressed and is involved in several
pathophysiological processes associated with
cardiovascular complications in CKD, for example
vascular calcification, chronic inflammation, oxidative
stress, and fibrosis.
 BET inhibitors and microRNAs are epigenetic modulators
with the potential to simultaneously target several different
pathogenic mechanisms upregulated in chronic diseases.
 The novel epigenetic modulator apabetalone targets
pathogenetic processes associated with the induction of
ALP and improves cardiovascular prognosis in high-risk
patients, including patients with CKD, while lowering
circulating ALP activity.
FIGURE 1. Alkaline phosphatase is ubiquitously expressed; how
tissues to the circulating alkaline phosphatase activity may vary. U
nonspecific isozyme alkaline phosphatase comprise approximatel
activity. Intestine alkaline phosphatase can comprise up to 10% o
with blood group B or 0, but less than 3% in individuals with bloo
disease-related outcomes, for example cardiovascular disease or
from specific tissues contributes to the total circulating alkaline ph
undetermined. Designed by Macrovector and Brgfx - Freepik.com
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1062-4821 Copyright  2019 The Author(s). Published by Wolters KluweALKALINE PHOSPHATASE IN HEALTH
AND DISEASE
ALP is a ubiquitously expressed enzyme that cataly-
ses the hydrolytic removal of phosphate groups
from biochemical compounds [4]. Four different
isozymes are known in humans. The tissue-nonspe-
cific isozyme (TNALP) is expressed in different
organs, for example, bone, liver, kidneys, brain,
cardiovascular system, and leukocytes, whereas tis-
sue-specific isozymes are expressed in the intestine
(IALP), the placenta, and the testis (germ cell ALP)
[5]. In most healthy individuals, circulating total
ALP activity is comprised of approximately 50% of
bone-specific isoforms of TNALP (BALP) and an
equal percentage of liver-specific TNALP isoforms.
However, in patients with blood groups B and 0,
IALP can contribute up to 10%of the circulating ALP
activity. In individuals with blood group A, IALP
contributes less than 3% of total ALP activity, asever, the contribution of alkaline phosphatase from different
nder healthy conditions, liver and bone isoforms of tissue-
y 50% each of the total circulating alkaline phosphatase
f the circulating alkaline phosphatase activity in individuals
d group A. Circulating alkaline phosphatase predicts
mortality, but to which extend alkaline phosphatase derived
osphatase activity in pathologic conditions remains largely
.
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Novel therapeutic approaches in nephrology and hypertensionblood group A red cells bind IALP in the circulation.
ALP is an ectoenzyme attached to the outer layer of
cell membranes. It is released into circulation as a
soluble homodimer and cleared from the circulation
via hepatic asialoglycoprotein receptors after desia-
lylation by circulating neuraminidase [6–8].
TNALP is involved in the regulation of biomin-
eralization, inflammation, oxidative stress and
endothelial dysfunction, fibrosis, and cellular
hypertrophy [9
&
,10–12]. TNALP dephosphorylates
compounds of the extracellular matrix quite unspe-
cifically. Known biological functions of ALP include
the inactivation of calcification inhibitors, the
dephosphorylation of nucleotides in purinergic sig-
naling, the activation of matrix metalloproteinases
(MMPs), and the local regulation of vitamin B6
metabolism (Fig. 2). IALP contributes to the regula-
tion of the gut microbiome, nutrient uptake, and
the systemic immune response [5].
ALP is present in many species including
humans, and is routinely applied as a marker for
liver disease or bone turnover; however, until
recently, its biologic relevance was poorly under-
stood. Similar to the evolutionary science behindFIGURE 2. Summary of mechanisms linking dephosphorylation
processes. LPS, lipopolysaccharides; MMP, metalloproteinase; OP
pyridoxalphosphate; PPi, pyrophosphate.
6 www.co-nephrolhypertens.comthe emergence of the C-reactive protein (CRP) from
an inflammatory modulator to now a novel CVD
marker, over the past 2 decades, ALP, too, has been
emerging with newly discovered roles in biological
homeostasis [9
&
]. Emerging evidence suggests that
circulating ALP is a strong predictor of adverse car-
diovascular outcome and all-cause mortality [9
&
]. In
spite of being a novel cardiovascular risk marker and
potential therapeutic target for cardiovascular risk,
no clinical stage therapeutics aimed at lowering
serum ALP are available to date.Alkaline phosphatase and biomineralization
Biomineralization is regulated by a complex inter-
play of calcification promotors and inhibitors. In
CKD, disturbance of this interplay is common and
can cause extensive soft-tissue calcification such as
medial artery calcification or calcification of athero-
sclerotic plaques. ALP is essential for bone minerali-
zation, as demonstrated by hypophosphatasia, a
hereditary disease with loss-of-function muta-
tions of the ALPL gene that encodes TNALP [13].
In addition, ALP plays a central role in pathologicalby alkaline phosphatase to normal and pathophysiological
N, osteopontin; Pi, phosphate; PL, pyridoxal; PLP,
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enhanced in matrix vesicles derived from minerali-
zation-competent cells. These vesicles function as
nidi for matrixmineralization. The process is similar
in physiologically mineralizing tissues, such as bone
and dentin, and in pathological soft-tissue calcifica-
tion. ALP promotes the propagation of matrix min-
eralization by dephosphorylation of mineralization
inhibitors such as pyrophosphate and the phospho-
protein osteopontin, and by generation of inorganic
phosphate, rendering a more procalcific extracellu-
lar milieu [16–18]. A role in the regulation of addi-
tional phosphoproteins in the extracellular matrix
can be speculated. Matrix Gla protein (MGP) is one
of the most important physiological mineralization
inhibitors [19]. Its activity is determined by post-
translational phosphorylation in addition to vita-
min K-dependent carboxylation [20,21]. The effect
of MGP inhibition by pharmacological vitamin K
antagonists on the propagation of medial artery
calcification and calcific uremic arteriolopathy in
CKD is well known [22,23]. Lower circulating levels
of the nonphosphorylated form of MGP are associ-
ated with vascular calcification and mortality in
dialysis patients, independent of its carboxylation
status [24]. However, the mechanisms of MGP
dephosphorylation are yet unknown and a role
for ALP in this process can only be hypothesized.Alkaline phosphatase and fibrosis
A novel mechanism has been suggested for ALP in
fibrosis and cardiovascular fibrocalcification, which
is a feature of congestive heart failure [25]. The
upregulation of ALP in cardiac myocytes leads to
increased fibrosis via dephosphorylation of metal-
loproteinases 2 and 9 [26]. Indeed, increased circu-
lating ALP activities have been observed in CKD
patients with myocardial hypertrophy and conges-
tive heart failure [27–29]. Further, ALP in bron-
choalveolar lavage has been identified as a marker
of pulmonary fibrosis, connecting ALP to fibrotic
processes in the lung [30].Alkaline phosphatase and inflammation
Several mechanisms link ALP to inflammation. Cir-
culating ALP correlates well with circulating CRP,
and ALP has been suggested as a component of the
hepatic acute phase reaction [31]. Also, circulating
IALP is enhanced in inflammatory conditions [32].
However, CRP and inflammatory cytokines have an
inhibitory effect on ALP activity in osteoblasts
[33,34] as circulating CRP was only associated with
total ALP, not BALP, in a large cohort of dialysis
patients [35], suggesting an extra-skeletal source for1062-4821 Copyright  2019 The Author(s). Published by Wolters Kluwethe increased circulating ALP activity during inflam-
mation. In contrast to the effect of inflammation on
ALP in bone, inflammatory mediators can increase
ALP activity in vascular smooth muscle cells
(VSMCs) and mesenchymal stem cells [36,37],
which is concordant with the clinical finding of
opposing effects of inflammation on bone versus
vascular mineralization in CKD [38]. ALP modulates
the cellular inflammatory response via purinergic
signaling by contributing to the enzymatic conver-
sion of proinflammatory extracellular adenosine tri-
phosphate to anti-inflammatory adenosine [39].
ALP is also expressed by inflammatory cells in the
vascular wall, and may mediate a link between
inflammation and vascular calcification, commonly
seen in the atherosclerotic plaque and in diseases of
the metabolic syndrome, such as type 2 diabetes
mellitus and CKD [40–43].
Sepsis-induced inflammation can cause acute
kidney injury and loss of renal function that leads
to morbidity and mortality [44]. Serum ALP predicts
infection-related mortality [45] and has been pro-
posed as a component of a clinical prediction model
for bacteremia in CKD stage 5D patients [46]. Circu-
lating ALP has the potential to inactivate endo-
toxins and other highly phosphorylated
proinflammatory compounds [31,32]. Intestinal
ALP detoxifies lipopolysaccharide (LPS) to reduce
its inflammatory properties and interaction with
Toll-like receptors and prevents inflammation in
zebrafish in response to the gut microbiota [47].
Indeed Resolvin E1-induced intestinal ALP pro-
motes resolution of inflammation through LPS
detoxification [48]. This concept is being challenged
in clinical trials. For example, in patients with acute
kidney injury and sepsis, injection of recombinant
ALP promoted a decrease in all-cause mortality,
supporting a physiological role for ALP inmitigating
the deleterious and morbid actions arising from
sepsis [49]. Hence, similar to CRP, there is a biologi-
cally plausible role for increased levels of ALP under
such pathologic circumstance, which may elicit
maladaptive consequences. IALP may also exert a
protective effect against inflammation-induced
complications of diabetes mellitus type 1, such as
CVD or diabetic nephropathy [50].Alkaline phosphatase and oxidative stress
Increased oxidative stress is associated with adverse
cardiovascular outcomes [51]. Oxidative stress indu-
ces ALP and calcification in calcifying vascular cells
[52]. Increased oxidative stress is also associated
with osteoporosis [53] because mineralization is
inhibited in osteoblasts [52]. The reduction of car-
diovascular oxidative stress in CKD patients byr Health, Inc. www.co-nephrolhypertens.com 7
Novel therapeutic approaches in nephrology and hypertensionexercise treatment is associated with a reduction of
circulating ALP [54]. However, the origin of the
increased serum ALP activity in patients with oxida-
tive stress has yet to be determined.Alkaline phosphatase and hypertension
ALP contributes to regulation of hypertension and
vascular tone. Inhibition of ALP in isolated perfused
kidneys and in experimental animals in vivo
decreased the hypertensive blood pressure (BP)
response to norepinephrine [55]. The effect is par-
tially explained by the role of ALP in purinergic
signaling and increased adenosine production. Cir-
culating ALP activity is inversely correlated to
maximal vasodilatory response to acetylcholine,
indicative of endothelial dysfunction [56]. An addi-
tional mechanism linking ALP to BP control is the
association with arterial stiffness [57], possibly
explained by vascular calcification [58]. A contribu-
tion of ALP to increased fibrotic transformation of
capacity arteries can also be speculated [59].Alkaline phosphatase and cognitive
impairment
Circulating ALP is associated with impaired cogni-
tion [60–62]. Cognitive impairment is a serious
complication in ageing andCKD.Underlying abnor-
malities include neurodegenerative processes and
impaired microcirculation. In Alzheimer’s disease,
ALP in the brain and circulation is inversely corre-
lated with cognitive function, and dephosphoryla-
tion of tau has been suggested as a putative
pathomechanism [63]. Increased circulating ALP is
also associated with cerebral small vessel disease, a
hallmark of vascular cognitive impairment [64].
ALP contributes to the regulation of gamma amino-
butyrate and other neurotransmitters [65]. The
association of reduced circulating ALP after parathy-
roidectomy in CKD patients with improved cogni-
tion suggests a possible therapeutic implication for
ALP lowering in cognitive impairment [66].Alkaline phosphatase in chronic kidney
disease
In CKD, circulating ALP is commonly used in con-
junction with parathyroid hormone for the approx-
imation of bone turnover due to its association with
bone formation [10,67]. In the absence of liver
disease, variations in total ALP typically arise from
BALP, and can identify extremes of high and low
bone turnover [68]. Furthermore, circulating ALP is
a better predictor of incident fractures in dialysis
patients than bonemineral density [69]. Circulating8 www.co-nephrolhypertens.comALP is also a strong and independent predictor of
mortality and cardiovascular complications in CKD
[9
&
]. In non-CKD populations, the association
between ALP and inflammation is predictive of
mortality [35]. In contrast, circulating BALP levels
in patients with advanced CKD are an even stronger
predictor ofmortality than total ALP [70]. This could
be due to its association with the extensive vascular
calcification arising in patients with CKD on dialysis
[71]. As all of the pathomechanisms discussed above
are upregulated in CKD [3], the contribution of ALP
to the increased CKD-related mortality, cardiovas-
cular complications, and impaired cognition is
presumably multifactorial.REGULATION OF ALPL GENE EXPRESSION
Human TNALP is encoded by the ALPL gene (acces-
sion number, NM_000478), which is located on the
short arm of chromosome 1, 1p36.12 [72–74]. The
ALPL gene exceeds 50kb and comprises 12 exons.
The first exon is part of the 50-untranslated region of
the TNALP mRNA, which consists of either exon 1A
or 1B that respond to different promoters and results
in two mRNAs, each encoding an identical polypep-
tide, but with different 50-untranslated regions [75].
The expression of TNALP is ubiquitous; however,
transcription of the two variants of exon 1 results in
cell-specific and tissue-specific expression. One of
these transcripts is termed ‘bone ALPL transcript’ in
active osteoblasts comprising exon 1A, whereas
exon 1B is driven by a separate promoter active in
liver and kidney tissues [75,76].
The regulation ofALPL expression is best studied
in osteoblast-like cells. Bone formation by cells from
the osteoblast lineage and functional actions, for
example, biomineralization, involvemultiple devel-
opmental signals such as hormones, growth factors,
cytokines, Wingless-related integration site (WNT)
ligands, and bone morphogenetic proteins. In addi-
tion, there are also several transcription factors that
regulate the expression of a variety of osteoblast-
specific genes expressing proteins pivotal for
biomineralization, for example, collagen type I,
bone-specific alkaline phosphatase, and osteocalcin
[77]. The bone essential transcription factor runt-
related transcription factor 2 (Runx2) has been iden-
tified as the master regulator for osteoblast differen-
tiation [78]. Osterix (Osx; Sp7 gene), a zinc finger-
containing transcription factor with a Runx2-bind-
ing sequence, is also essential for osteoblast differ-
entiation and bone mineralization. Osx is not
expressed in Runx2-deficient mice, whereas the
expression of Runx2 is not affected in Osx-deficient
mice [79], which implies that Osx regulates osteo-
blast differentiation downstream of Runx2 [80].Volume 29  Number 1  January 2020
Pharmacologic epigenetic modulators of alkaline phosphatase Haarhaus et al.Other key transcription factors involved in osteo-
blast differentiation are the homeobox gene Msx2
and members of the distal-less homeobox (Dlx)
family. Msx2 represses the expression of ALPL by
directly binding to its promoter, whereas Dlx5 acti-
vates ALPL expression by interfering with the action
of Msx2 [81]. Dlx3 is another potent regulator of
Runx2 activation during osteogenic differentiation
[82]. It has also been demonstrated that overexpres-
sion of Dlx2 has no effect on RUNX2, DLX5, and
MSX2 expression upon osteogenic induction, but
stimulated ALPL and osteocalcin expression [83].
Thus, Dlx2 may directly upregulate ALPL to
promote osteoblastogenesis.EPIGENETIC REGULATION OF ALKALINE
PHOSPHATASE
The term Epigenotype was coined in 1942 by Wad-
dingtonwho concluded that ‘between genotype and
phenotype lies a whole complex of development
processes’ [84]. The modern definition of epige-
netics includesmodifications of DNA and associated
proteins, not involving changes to the underlying
DNA sequence, that are influenced by the environ-
ment andmaintained during cell division that cause
stable changes in gene expression [85
&
]. The main
epigenetic factors are DNA methylation, posttrans-
lational changes of histones, and higher order chro-
matin structure. Post translational modifications of
histones impact chromatin structure, accessibility,
and recruitment of transcription machinery to
dictate whether genes are switched on or off. These
dynamicmodificationsorchestrate cellular responses
toenvironmental, developmental, ormetabolic stim-
uli throughmodification of the transcriptome. How-
ever, epigenetics can underlie dysregulated gene
expression in disease states including cancer [86]
and pathological inflammatory processes [87].
Enzymes or proteins that generate or interact with
epigenetic alterations can be classified as writers,
erasers, or readers, depending on whether they
add, remove, or recognize a posttranslational modi-
fication (Fig. 3).Histone acetylation
Histone acetylation is associated with open chro-
matin structure, accessibility for transcription
factor binding, and active transcription [88
&
]. His-
tone acetylation impacts TNALP expression. His-
tone deacetylase inhibitors (HDACi) increase
chromatin acetylation. In vitro, HDACi-induced
expression of ALPL and promoted osteogenic dif-
ferentiation of human mesenchymal stem cells
[89]. Mechanistically, histone acetylation has been1062-4821 Copyright  2019 The Author(s). Published by Wolters Kluweassociated with the regulation of bone morphoge-
netic proteins, WNT signaling, and RUNX2 induc-
tion [90]. Whether acetylation directly impacts
promoters of ALPL expression is an area of
ongoing research.DNA methylation
Studies have demonstrated that the ALPL promoter
A1E is highly methylated [91]. Delgado-Calle et al.
[92], demonstrated that DNA methylation has an
important role in the modulation of ALPL expres-
sion in human osteoblast-like cells. They showed an
inverse relationship between themethylation status
of a CpG island extending from 579 to þ836bp of
the ALPL gene including the promoter region,
which implies that epigenetic regulation by DNA
demethylation strongly enhances TNALP expres-
sion and activity [92]. In VSMC, both phosphate
and hydroxyapatite nanocrystals modulate DNA
methylation, which results in an increased ALP
activity and the induction of an osteoblast-like
phenotype [93,94].MicroRNAs
Long noncoding RNAs and microRNAs (miRNAs)
are also key epigenetic factors that are involved in
posttranscriptional gene regulation [77,95
&
]. The
miRNAs are small noncoding single-stranded RNA
molecules, approximately 18–25 nucleotides, that
inhibit protein synthesis by binding to the 30-
untranslated region of mRNA to block protein trans-
lation and/or modulate mRNA stability. It has been
estimated, through computational predictions, that
more than 50% of all human protein-coding genes
are potentially regulated by miRNAs [96]. Bone-reg-
ulating miRNAs play a key role in osteogenic differ-
entiation and signaling pathways involved in
osteogenesis [77,95
&
,97,98]. The key transcription
factors Runx2 and Osx are downregulated by
numerous miRNAs in pluripotent mesenchymal
cells to suppress the bone phenotype in nonosseous
cells and tissues [77,99].
Some miRNAs have been found to suppress and
promote distinct signaling pathways related with
osteogenic differentiation [95
&
,100
&
]. Reduced
mRNA expression for collagen I, TNALP, and osteo-
calcin has been found while overexpressing miR-
375, thus suggesting thatmiR-375 is able to suppress
osteogenic differentiation by targeting Runx2 [101].
Overexpression of miR-133a-5p has also been
reported to inhibit ALPL expression and mineraliza-
tion through targeting Runx2 [102]. Li et al. [103],
demonstrated that miR-216a promoted osteoblast
differentiation and enhanced bone formation.r Health, Inc. www.co-nephrolhypertens.com 9
FIGURE 3. Chromatin is comprised of DNA and proteins that generate a compact structure critical for packaging and stability
of eukaryotic chromosomes. The primary protein components are histones, around which the DNA is wound to form a
nucleosome. Epigenetics involves covalent modifications to chromatin that does not affect the underlying DNA sequence.
Covalent modifications to chromatin impact both chromatin structure and recruitment of transcription complexes that, in effect,
switch genes on or off. These dynamic epigenetic modifications are carried out by adding (writing) and removing (erasing)
posttranslational modifications, followed by ‘reading’, which dictates gene expression and eventual phenotypic response.
Novel therapeutic approaches in nephrology and hypertensionPHARMACOLOGIC EPIGENETIC
INTERVENTIONS TARGETING ALKALINE
PHOSPHATASE
MicroRNAs
Given the ubiquitous expression of ALP, its central
role in biomineralization and the high incidence of
vascular calcification in patients with CKD, it is
reasonable to explore pharmacologic epigenetic
modulation of ALP as a potential therapeutic mea-
sure aimed at the prevention of cardiovascular com-
plications in CKD [9
&
]. Recent evidence indicates
that miRNAs are deregulated in CKD – mineral and
bone disorder [104]. Experimental studies support
the concept that miRNAs are potential targets to
ameliorate vascular calcification [100
&
]. According
to the miRBase version 22, sequences of 2656
mature human miRNAs have been catalogued so
far [105]. Hence, it is a challenging task to include10 www.co-nephrolhypertens.commost of the miRNAs that have been investigated
over the years in this review. However, recent data
demonstrate that phosphate-induced aortic calcifi-
cation trigger miRNA modulation by upregulating
miR-200c, miR-155 and miR-322, whereas miR-708
and miR-331 were downregulated [106
&
]. Other
miRNAs that are involved in vascular calcification,
thus potential treatment targets, are miR-29a/b,
miR-30d/e, miR-125b, miR-135a, miR-143, miR-
145, miR-204, miR223 and miR-762 [107]. Most of
these miRNAs target the two main transcription
factors Runx2 and Osx that influence TNALP activ-
ity and biomineralization. Undoubtedly, miRNAs
have a key role in regulating the progression of
vascular calcification; however, the high abundance
ofmiRNAs requires extended large-scale epigenome-
wide studies to fully exploit the potential of epige-
netic regulation by miRNAs for novel therapeutic
approaches to ameliorate vascular calcification.Volume 29  Number 1  January 2020
FIGURE 4. Chromatin acetylation is an epigenetic modification associated with open chromatin structure and active
transcription. Bromodomain and extraterminal proteins are ‘chromatin readers’ that bind acetylated lysine on histones or
transcription factors via two tandem bromodomains 1 and 2 and recruit transcriptional machinery (e.g. positive transcription
elongation factor and RNA polymerase II) to drive expression of bromodomain and extraterminal sensitive genes. Apabetalone
is an orally available small molecule inhibitor of bromodomain and extraterminal bromodomains that causes bromodomain
and extraterminal protein release from chromatin and, as a consequence, downregulation of bromodomain and extraterminal
sensitive gene transcription. Apabetalone preferentially targets bromodomain 2 (represented by yellow halo), a characteristic
that differentiates it from pan-bromodomain and extraterminal inhibitors that bind bromodomains 1 and 2 with equal affinity.
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Bromodomain and extraterminal (BET) proteins
BRD2, BRD3, BRD4, and BRDT are chromatin read-
ers that not only bind acetylated lysine on histone
tails and transcription factors via bromodomains 1
and 2, but also recruit transcriptional machinery to
regulate gene expression [108]. BET inhibitors (BETi)
block the interaction of BET proteins with acetylated
histones or transcription factors to impact expres-
sion of target genes [88
&
]. Apabetalone is an orally
available BETi in clinical development for treatment
of CVD. It preferentially binds bromodomain 2 in
BET proteins (Fig. 4), which distinguishes it from
pan-BETi that target bromodomains 1 and 2 with1062-4821 Copyright  2019 The Author(s). Published by Wolters Kluweequal affinity [109]. In clinical trials, apabetalone
treatment reduced major adverse cardiac events
(MACE) in patients with CVD, and was associated
with 44% relative risk reduction on top of standard
of care [110
&
]. The reduction of MACE by apabet-
alone was associated with a reduction of serum ALP,
independent of traditional cardiovascular risk fac-
tors and inflammation [111
&
]. Studies showed this
drug concurrently modulated factors that promote
atherosclerotic plaque stabilization and MACE
reduction. HDL cholesterol increased [110
&
,112],
while the complement cascade, acute phase reac-
tion, and mediators of vascular inflammation were
suppressed [113,114].r Health, Inc. www.co-nephrolhypertens.com 11
Novel therapeutic approaches in nephrology and hypertensionIn CKD patients with a history of CVD, apabet-
alone treatment improved kidney function and
reduced circulating levels of ALP [115]. Mechanisti-
cally, apabetalone downregulated ALPL expression
in primary human hepatocytes and VSMC [116
&
],
and as a consequence, reduced TNALP protein levels
and enzymatic activity. Small molecule inhibitors of
TNALP have been evaluated as a therapeutic for
vascular calcification [14], however, apabetalone
may be the first clinical stage molecule to modify
TNALP production. In vitro, apabetalone opposed
calcification of VSMCs cultured in osteogenic con-
ditions through an epigenetic mechanism involving
BRD4 that suppressed induction of procalcific genes,
including RUNX2 and ALPL [116
&
].
A single dose of apabetalone in CKD stage 4–5
patients rapidly resulted in reduction of numerous
inflammatory cytokines, including IL-6 [2]. In the
same study, proteomic profiling of more than 1300
plasma proteins predicted several immune and
inflammatory pathways were activated in patients
with impaired kidney function, including nuclear
factor kB (NF-kB), IL-6, or bone morphogenetic pro-
tein signaling. These canonical pathways were
downregulated with one dose of apabetalone, which
would favourably impact progression of renal
impairment and associated vascular calcification.Bromodomain and extraterminal inhibition in
metabolic bone disorders: implication for
renal osteodystrophy
Distinct preclinical models of metabolic bone dis-
eases have demonstrated that BETi do not diminish
bone structure or mechanical properties, and may
instead increase bone volume and restore mechani-
cal strength [117–120]. These studies show that
beneficial effects of BETi on bone disorders stems
from anti-inflammatory effects, as well as epigenetic
modulation of key factors in bone remodelling,
including TNALP. N-methylpyrrolidone (NMP) is a
U.S. Food and Drug Administration-approved drug
excipient identified as a bioactive BETi [121]. Studies
with NMP in preclinical models of bone degenera-
tion have positioned BETi as a pharmacologic strat-
egy for the prevention or treatment of bone diseases
characterized by excessive bone resorption. Numer-
ous studies have demonstrated BETi suppresses
inflammatory responses mediated by TNFa and
NF-kB [3,122–124]. NMP promoted growth of min-
eralized bone that was blocked by TNFa and recov-
ered TNFa-inhibited expression of essential
osteoblastic genes, including ALPL, RUNX2 and
SP7/Osterix [125]. In addition, NMP promoted bone
regeneration by enhancing BMP2 signaling in osteo-
blasts [126] and inhibited osteoclast differentiation12 www.co-nephrolhypertens.comto attenuate bone resorption induced by receptor
activator of NF-kB ligand [127]. NMP was shown to
increase osteoblast viability during hypoxia, and
countered hypoxia-mediated downregulation of
key genes involved in mineralization, including
ALPL [128]. Mechanistically, the NMP treatment
was protective in maintaining osteoblast differenti-
ation during hypoxia in part by inhibiting NF-kB
signaling. NMP preserved bone mineral density and
quality of bones in ovariectomized rats [121], essen-
tially ameliorating estrogen depletion-induced oste-
oporosis. Results were verified in similar studies
using N,N-dimethylacetamide [127], or the more
potent BETi JQ1, where treatment actually reversed
bone loss induced by estrogen deficiency [117].
These data imply that BETi therapy can increase
bone mass and improve bone turnover in inflam-
matory bone disorders and potentially in CKD.
CONCLUSION
Circulating ALP is a robust and independent risk
marker for CVD andmortality in the general popula-
tion and in CKD. The ubiquitous expression of ALP
and its involvement in several pathophysiologic pro-
cesses associated with CVD, bone disease, CKD pro-
gression, and cognitive dysfunction renders it
suitable for multifactorial epigenetic interventions.
Positive results from clinical studies with the novel
BETi apabetalone implicate a role forALPas apossible
novel cardiovascular treatment target. Experimental
studies with additional BETis and miRNAs suggest a
wider therapeutic potential for epigenetic modula-
tion of ALP. Further research is required to defini-
tively establish ALP as a clinical treatment target
levels and to elucidate the effect of lowering of
serum ALP towards specific targets levels on clinical
outcomes.
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